Iterative Mapping Grant Program

The Iterative Mapping Grant Program is your chance to get free access to single-molecule proteomic analysis on the Nautilus Voyager™ Platform. Grant awardees will participate in the Iterative Mapping Early Access Program at no charge and have 12 of their samples analyzed using either the AKT1 or EGFR Proteoforms Assay, both of which are currently under development.

Epitopes defining AKT1 proteoforms quantified by the assay may include:

  • pS124
  • pS129
  • pT308
  • pT450
  • pS473

Epitopes defining EGFR proteoforms quantified by the assay may include:

  • pT654
  • pT669
  • pY1045
  • pS1046/1047
  • pY1086
  • pY1173

The Nautilus AKT1 and EGFR Proteoforms Assays are designed to quantify the proteoform-defining patterns of phosphorylation found on intact AKT1 and EGFR molecules in your samples. Unique proteoforms and proteoform profiles may drive processes critical to cancer, but no platforms have been able to quantify them at scale until now.

To participate in the program, submit your project proposal using the form found here.

Additional details below and full terms and conditions here.

Additional details

Through the Iterative Mapping Grant Program, 3 awardees will participate in the Iterative Mapping Early Access Program at no charge. The winners will receive:

Analysis of 12 samples

Analysis of 12 samples (types and requirements listed below) on a timeline developed in consultation with Nautilus.

Experimental design assistance

Experimental design assistance in collaboration with Nautilus scientists.

Final proteoform data report

A final proteoform data report in an easy-to-interpret format.

Conference support

Support to present data at a mutually agreed-upon conference.

Publication assistance

Publication writing assistance for a peer-reviewed journal submission.

To be eligible for this grant, applicants must:

  • Submit a description of a 12-sample project by November 6, 2026 using the form above.
  • Have samples that meet program specifications available for shipment within 3 months (by February 5th, 2027).
  • Consent to allow Nautilus to announce that they are recipients of an Iterative Mapping Grant.
  • Consent to allow Nautilus to reference their work and data in marketing materials.
Winning grant submissions will be selected at the sole discretion of Nautilus Biotechnology.

Acceptable sample specifications

Samples must fall into one of the following types:
  • Cell lysate
  • Tissue lysate
Acceptable buffers:
  • RIPA lysis buffer (25 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, pH 8)
  • 2% SDS, 20 mM HEPES, pH 6.8
The amount of material required depends on the sample type.

Please contact marketing@nautilus.bio if you have questions about the requirements for your samples.

Example project ideas

Acceptable projects might focus on (non-exhaustive list):

Differentiating cancer subtypes by AKT1 and EGFR proteoform profiles.
Differentiating levels of cancer aggressiveness by AKT1 and EGFR proteoform profiles.
Identifying AKT1 and EGFR proteoforms produced during clearly defined stages of a cancer.
Determining which AKT1 and EGFR proteoforms are associated with specific signaling outcomes.
Identifying AKT1 and EGFR proteoforms associated with oncogenic mutations.
Identifying AKT1 and EGFR proteoforms produced in response to cancer-associated environmental risks.

All analysis services provided under this program are intended FOR RESEARCH USE ONLY and NOT FOR USE IN DIAGNOSTIC PROCEDURES.

Frequently asked questions

Who do I contact if I have more questions about my entry before I submit my applications?

Please email marketing@nautilus.bio, and we will contact you directly to discuss your entry.

When will I know if I have been selected to receive an Iterative Mapping Grant?

Winners will be announced on or before November 20, 2026.

How and where do I provide my samples?

Samples will be shipped to Nautilus Biotechnology’s Proteomics Analysis Services team in San Carlos, California. Specific shipping instructions and expectations will be discussed during an intake call.

Interested in joining our team?

View our open positions